<DOC>
	<DOCNO>NCT00726700</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , work different way stop growth cancer cell , either kill cell stop divide . Colony-stimulating factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . It yet know whether combination chemotherapy pegfilgrastim effective give without rituximab treat non-Hodgkin lymphoma . PURPOSE : This phase II trial study side effect give pegfilgrastim combination chemotherapy together without rituximab see well work treat old patient aggressive B-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Pegfilgrastim Combination Chemotherapy With Without Rituximab Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine side effect pegfilgrastim cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone ( CHOP ) without rituximab older patient aggressive B-cell non-Hodgkin lymphoma . - Determine adherence therapy regimens patient . - Determine antitumor effectivity immunochemotherapy . OUTLINE : This multicenter study . All patient receive prephase treatment comprise vincristine day -6 prednisone day -6 0 . Patients randomize 1 2 treatment arm . - Arm I ( without rituximab ) : Patients receive pegfilgrastim subcutaneously ( SC ) day 2 4 CHOP comprise cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 , oral prednisone day 1-5 . Treatment repeat every 2 week 6-8 course absence disease progression unacceptable toxicity . - Arm II ( rituximab ) : Patients receive pegfilgrastim CHOP 6-8 course arm I . They also receive rituximab ( administer 2 hour begin CHOP ) day 1 . Treatment rituximab repeat every 2 week 8 course . Patients bulky disease extranodal disease also undergo radiotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis CD20positive Bcell nonHodgkin lymphoma ( NHL ) Confirmed excisional biopsy lymph node sufficiently extensive biopsy extranodal involvement ( lymph node involvement ) Results immunohistological analysis expression CD20 antigen lymphoma cell must obtain Aggressive disease , include follow Bcell NHL Stage III follicular lymphoma Stage III follicular lymphoma diffuse Bcell lymphoma Lymphoblastic precursor Bcell lymphoma Diffuse large Bcell lymphoma , include follow subtypes : Centroblastic Immunoblastic Plasmablastic Anaplastic large cell Tcell rich Bcell lymphoma Primary effusion lymphoma Intravasal Bcell lymphoma Primary mediastinal Bcell lymphoma Mantle zone lymphoma Burkitt Burkittlike lymphoma Aggressive marginal zone lymphoma ( monocytoid ) All risk group allow Age adjust IPI 03 Previously untreated disease PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % No serious concurrent disease PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
</DOC>